Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADE + CHOP-Rituximab in Untreated DLBCL or MCL
NCT00151320Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Jan 2004
- Primary completion
- Apr 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), sponsored by Weill Cornell Medicine. Primary endpoints: Toxicity Profile and Maximum Tolerated Dose. Started Jan 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00151320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151320.